Previous trials utilising meal replacements on obese or T2DM patients have demonstrated significant improvements in HbA1c, weight, lipid profile, insulin sensitivity, and cardiovascular risk factors [47,48,49,50,51]. The gene discussed is INS; the disease is type 2 diabetes mellitus.